JP2017507931A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507931A5
JP2017507931A5 JP2016550261A JP2016550261A JP2017507931A5 JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5 JP 2016550261 A JP2016550261 A JP 2016550261A JP 2016550261 A JP2016550261 A JP 2016550261A JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5
Authority
JP
Japan
Prior art keywords
day
pharmaceutical composition
composition according
agent
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/014687 external-priority patent/WO2015120198A1/en
Publication of JP2017507931A publication Critical patent/JP2017507931A/ja
Publication of JP2017507931A5 publication Critical patent/JP2017507931A5/ja
Priority to JP2020144077A priority Critical patent/JP7328187B2/ja
Priority to JP2023126665A priority patent/JP7767361B2/ja
Pending legal-status Critical Current

Links

JP2016550261A 2014-02-05 2015-02-05 がん及び感染症の治療方法並びに治療用組成物 Pending JP2017507931A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020144077A JP7328187B2 (ja) 2014-02-05 2020-08-28 がん及び感染症の治療方法並びに治療用組成物
JP2023126665A JP7767361B2 (ja) 2014-02-05 2023-08-03 がん及び感染症の治療方法並びに治療用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936168P 2014-02-05 2014-02-05
US61/936,168 2014-02-05
PCT/US2015/014687 WO2015120198A1 (en) 2014-02-05 2015-02-05 Methods and compositions for treating cancer and infectious diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144077A Division JP7328187B2 (ja) 2014-02-05 2020-08-28 がん及び感染症の治療方法並びに治療用組成物

Publications (2)

Publication Number Publication Date
JP2017507931A JP2017507931A (ja) 2017-03-23
JP2017507931A5 true JP2017507931A5 (cg-RX-API-DMAC10.html) 2018-03-08

Family

ID=53778458

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016550261A Pending JP2017507931A (ja) 2014-02-05 2015-02-05 がん及び感染症の治療方法並びに治療用組成物
JP2020144077A Active JP7328187B2 (ja) 2014-02-05 2020-08-28 がん及び感染症の治療方法並びに治療用組成物
JP2023126665A Active JP7767361B2 (ja) 2014-02-05 2023-08-03 がん及び感染症の治療方法並びに治療用組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020144077A Active JP7328187B2 (ja) 2014-02-05 2020-08-28 がん及び感染症の治療方法並びに治療用組成物
JP2023126665A Active JP7767361B2 (ja) 2014-02-05 2023-08-03 がん及び感染症の治療方法並びに治療用組成物

Country Status (6)

Country Link
US (2) US11213583B2 (cg-RX-API-DMAC10.html)
EP (2) EP3102233B1 (cg-RX-API-DMAC10.html)
JP (3) JP2017507931A (cg-RX-API-DMAC10.html)
CN (1) CN105979961B (cg-RX-API-DMAC10.html)
CA (1) CA2937035A1 (cg-RX-API-DMAC10.html)
WO (1) WO2015120198A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
US11213583B2 (en) * 2014-02-05 2022-01-04 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
US20170165364A1 (en) * 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
ES2818800T3 (es) * 2014-06-11 2021-04-14 Idac Theranostics Inc Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
RU2745999C1 (ru) * 2014-12-05 2021-04-05 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии
EP3310384A1 (en) * 2015-06-17 2018-04-25 CureVac AG Vaccine composition
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018031507A1 (en) * 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2019088016A1 (ja) * 2017-10-30 2019-05-09 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物
KR102721494B1 (ko) * 2018-04-17 2024-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
EP3856207A4 (en) * 2018-09-27 2022-11-16 Genocea Biosciences, Inc. TREATMENT PROCESSES
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
US20230076515A1 (en) * 2019-11-18 2023-03-09 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
JP7814054B2 (ja) * 2020-01-30 2026-02-16 エーペックスイミューン セラピューティクス インコーポレイテッド Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物
CN115197320A (zh) 2021-04-07 2022-10-18 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体
IL322401A (en) * 2023-02-06 2025-09-01 Gmp Biotechnology Ltd MTOR therapies for cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
GB2302353B (en) 1995-06-21 1998-11-11 British Gas Plc Method of filling an excavated opening
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
CN101072578A (zh) 2004-10-29 2007-11-14 南加州大学 用共刺激分子的联合癌症免疫疗法
US20090317407A1 (en) * 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
JP2009539769A (ja) 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
ES2602459T3 (es) * 2008-12-26 2017-02-21 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-CD4
EP2375897A4 (en) 2009-01-14 2013-05-15 Health Research Inc METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
WO2010124498A1 (en) 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
WO2011139738A2 (en) * 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
US11213583B2 (en) * 2014-02-05 2022-01-04 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
ES2744936T3 (es) 2014-12-02 2020-02-26 Univ Tokyo Método para evaluar el efecto terapéutico de un agente antineoplásico que tiene un anticuerpo anti-CD4 como principio activo

Similar Documents

Publication Publication Date Title
JP2023133525A5 (cg-RX-API-DMAC10.html)
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US20230181605A1 (en) Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
EP3407911B1 (en) Methods and pharmaceutical composition for the treatment of cancer
JP2017501167A5 (cg-RX-API-DMAC10.html)
US12377094B2 (en) Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies
JP2018507220A (ja) がんの治療のための方法、組成物、及びキット
RU2017121096A (ru) Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1
JP2017537090A5 (cg-RX-API-DMAC10.html)
JP2019503387A5 (cg-RX-API-DMAC10.html)
KR20180105685A (ko) 투카레솔 또는 이의 유사체를 함유하는 조성물
US20220265823A1 (en) Uses of myostatin antagonists, combinations containing them and uses thereof
CN112351795A (zh) 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
JP2024016209A (ja) 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
WO2023240082A2 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
WO2019090330A1 (en) Methods of treating a tumor
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
WO2025190251A1 (zh) 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
CN102935228B (zh) 用于肿瘤治疗的试剂、其用途及方法
CN113573707A (zh) 用于治疗癌症的组合产品
US20250034255A1 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
WO2014198330A1 (en) Combination of cd37 antibodies with chlorambucil
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
JP2023536596A5 (cg-RX-API-DMAC10.html)